Skip to content

Cohort Study on the Construction of a Diagnostic Model and Prognostic Model for Primary Aldosteronism through Multiomics Joint Analysis

Study on the Construction of a Diagnostic Model and Prognostic Model for Primary Aldosteronism through Multiomics Joint Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086963
Enrollment
Unknown
Registered
2024-07-16
Start date
2024-07-23
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism

Interventions

Primary Aldosteronism Group:No intervention

Sponsors

The First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. According to the Expert Consensus on the Diagnosis and Treatment of Primary Aldosteronism (2020 Edition), diagnosis is mainly made through clinical manifestations, screening tests, and diagnostic tests, with available baseline data; 2. Age range from 18 to 80 years old, regardless of gender. 3.After surgery, the participants met the inclusion criteria and voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to undergo adrenal venous blood sampling (AVS); 2. Suspected of autonomous cortisol secretion; 3. In the stage of active liver disease or with significant liver function damage, defined as alanine aminotransferase (ALT) = 2.5 times the upper limit of the normal range; 4. Those who have mental disorders, are unwilling to communicate with others, or have language barriers that prevent them from fully understanding the research plan or cooperating with researchers; 5. Patients with severe cardiopulmonary dysfunction and malignant tumors; 6. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Steroid hormone profile;Metabolomics spectrum;

Secondary

MeasureTime frame
Blood pressure;Aldosterone;

Countries

China

Contacts

Public ContactPEIWEN WU

The First Affiliated Hospital of Fujian Medical University

hehe0409@qq.com+86 591 8798 1683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026